Loading
A phase 3 trial testing OSE2101 in non-small-cell lung cancer, now recruiting.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor is a phase 3 interventional study registered as NCT06472245, led by OSE Immunotherapeutics with Exystat and GeneDx, and recruiting on the registry. Official title: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor. Planned enrolment is 363 participants (estimated). The study started in 2024-12-03 and primary completion is expected in 2027-12-15. No results have been posted on ClinicalTrials.gov.